The US National Institutes of Health has granted $1.5m to P2D Bioscience to develop a safe dopamine transport inhibitor.
P2D Bioscience said pre-clinical testing and numerous scientific publications indicate that PD2007 inhibits dopamine transport in multiple brain regions.
In addition to its inhibiting activity, PD2007 demonstrates no abuse potential, whereas other approved dopamine transport inhibitors which are classed as Schedule II drugs under the US Controlled Substances Act.
Further, PD2007 demonstrates no functional effects on blood pressure and heart rate, unlike other approved dopamine transport inhibitors.
P2D Bioscience plans to raise private equity funding for clinical safety and efficacy studies of PD2007, as well as to support testing of its proprietary TNF-alpha inhibitors.
